TY1A-LR2 Antibody

What is TL1A and why is it important in research?

TL1A is a type II transmembrane protein belonging to the TNF superfamily (TNFSF15). It consists of a 35 amino acid cytoplasmic domain, a 24 amino acid transmembrane region, and a 192 amino acid C-terminal extracellular domain. TL1A is predominantly expressed in endothelial cells, and its expression can be induced by pro-inflammatory cytokines like TNF-alpha and IL-1 alpha .

TL1A is significant in research because it acts as a ligand for death receptor 3 (DR3, also known as TNFRSF25), which is primarily expressed on activated T cells. Depending on cellular context, this interaction can trigger either NF-κB activation and pro-inflammatory cytokine secretion or induce caspase activity and apoptosis, making it a critical molecule for understanding inflammatory and immune response mechanisms .

What detection methods can be used with TL1A antibodies?

Based on validated research protocols, TL1A antibodies can be effectively employed in multiple detection methods:

• Western Blot: TL1A antibodies can detect specific bands at approximately 22 kDa in human samples like HT-29 colon adenocarcinoma cell lysates and pancreas tissue under reducing conditions .

• Flow Cytometry: TL1A antibodies are useful for detecting expression in various cell types including peripheral blood mononuclear cells (PBMCs) and cancer cell lines like HT-29 .

• Immunohistochemistry: These antibodies can be used for tissue section analysis, as demonstrated in human prostate cancer tissue where TL1A localization in epithelial cell cytoplasm has been observed .

What sample types are compatible with TL1A antibody detection?

TL1A antibodies have been validated for detecting the target protein in:

• Human cell lines (including HT-29 human colon adenocarcinoma cells)

• Human primary cells (such as peripheral blood mononuclear cells)

• Human tissue samples (including pancreas and prostate cancer tissues)

• In vitro culture systems (for functional assays such as apoptosis studies in TF-1 erythroleukemic cells)

How can I optimize TL1A antibody dilutions for various applications?

Optimizing antibody dilutions requires methodical testing based on application-specific parameters:

For Western Blot:

• Begin with 1 μg/mL concentration as demonstrated with HT-29 cell lysates

• Test reducing conditions using appropriate buffer systems (e.g., Immunoblot Buffer Group 1)

• Validate specificity by confirming the expected molecular weight (~22 kDa for TL1A)

For Flow Cytometry:

• Initial dilutions should account for cell type-specific expression levels

• Include appropriate isotype controls (e.g., Rabbit IgG control antibody)

• Consider co-staining with lineage markers (such as CD4 for T lymphocytes) to identify specific populations expressing TL1A

For Immunohistochemistry:

• Start with 0.3 μg/mL concentration for paraffin-embedded sections

• Implement heat-induced epitope retrieval with appropriate buffers (e.g., Antigen Retrieval Reagent-Basic)

• Optimize incubation times and temperatures (typical protocol: 1 hour at room temperature)

The optimal dilution should be determined empirically for each laboratory and application, as variables like sample preparation methods and detection systems will influence results.

What methodological approaches can resolve inconsistent TL1A detection results?

When encountering reproducibility issues with TL1A antibody applications, consider these troubleshooting approaches:

• Sample preparation optimization:

  • For cell lysates, ensure complete lysis using appropriate detergents

  • For tissues, optimize fixation duration and conditions to preserve epitope integrity

  • Consider native versus denatured conditions based on the antibody's epitope recognition profile

• Signal amplification strategies:

  • For low abundance detection, employ secondary antibody systems with higher sensitivity

  • Consider enzyme-conjugated secondary detection systems with appropriate substrates

  • Implement counterstaining approaches that enable clear discrimination of positive signals

• Validation approaches:

  • Use multiple antibody clones targeting different epitopes

  • Confirm specificity with appropriate positive and negative controls

  • Implement knockdown/knockout validation where possible to confirm specificity

How can TL1A antibodies be used to study apoptosis mechanisms?

TL1A has demonstrated capacity to induce apoptosis in certain cell types, making anti-TL1A antibodies valuable tools for mechanistic studies:

Neutralization approach methodology:

• Culture appropriate target cells (e.g., TF-1 human erythroleukemic cells) in standard conditions

• Add recombinant human TL1A protein (typically 80 ng/mL) to induce apoptosis

• Add varying concentrations of anti-TL1A neutralizing antibody (typical range: 0.04-0.2 μg/mL)

• Measure apoptosis using appropriate detection methods (e.g., Resazurin-based assays)

• Calculate neutralization dose (ND50) by plotting antibody concentration versus apoptotic response

This approach allows researchers to:

• Quantify TL1A-specific apoptotic effects versus background cell death

• Determine the potency of TL1A in different cellular contexts

• Investigate downstream signaling mechanisms through inhibitor studies combined with neutralization

What considerations are important for studying TL1A in inflammatory contexts?

When investigating TL1A's role in inflammatory pathways:

• Cell type selection is critical:

  • Primary T cells typically respond to TL1A with NF-κB activation and proinflammatory cytokine secretion

  • Tumor cell lines may demonstrate predominantly apoptotic responses

  • Endothelial cells represent physiological sources of TL1A expression

• Signaling pathway analysis approach:

  • Design experiments to distinguish between NF-κB activation versus caspase-dependent pathways

  • Consider the regulatory role of decoy receptor 3 (DcR3/TR6/TNFRSF6B) which competes with DR3 for binding to TL1A

  • Incorporate time-course analysis to distinguish between immediate versus delayed signaling events

• Integration with in vivo models:

  • TL1A has been shown to promote ex vivo splenocyte expansion

  • It enhances in vivo graft-versus-host responses

  • Consider these functional readouts when designing translational research protocols

How do TL1A expression patterns differ across tissue and disease contexts?

Based on immunohistochemical and molecular studies:

• Normal tissue distribution:

  • Predominantly expressed in endothelial cells

  • Expression can be induced by inflammatory stimuli (TNF-alpha, IL-1 alpha)

  • Expression in immune cell subsets is tightly regulated

• Cancer contexts:

  • Detectable in epithelial cells of prostate cancer tissues

  • Present in colon adenocarcinoma cell lines (HT-29)

  • Expression patterns may reflect tumor microenvironment inflammatory status

• Methodological approach for comparative analysis:

  • Use standardized immunohistochemistry protocols across tissue types

  • Implement digital quantification of staining intensity

  • Consider multiplexed approaches to correlate with inflammatory markers

What strategies can be employed to study TL1A's role in T cell costimulation?

TL1A acts as a costimulatory factor for T cells, inducing NF-κB activation and enhancing IL-2 responsiveness and proinflammatory cytokine secretion. Research strategies include:

• Functional T cell assays:

  • Measure T cell proliferation in response to TL1A stimulation with/without TCR engagement

  • Quantify cytokine production profiles using ELISA or intracellular cytokine staining

  • Assess IL-2 receptor upregulation and signaling pathway activation

• Molecular approaches:

  • Analyze DR3 expression levels on different T cell subsets

  • Investigate NF-κB pathway activation using reporter assays or phosphorylation studies

  • Examine the competition between membrane-bound and soluble TL1A forms

• Translational research considerations:

  • Study TL1A's role in graft-versus-host responses

  • Investigate potential therapeutic targeting of the TL1A-DR3 axis in autoimmune contexts

  • Examine the role of the TL1A-DR3 interaction in T cell memory formation

What are the optimal storage conditions for maintaining TL1A antibody activity?

To preserve antibody functionality:

• Long-term storage: Store at -20°C to -70°C for up to 12 months from the date of receipt

• Medium-term storage: After reconstitution, store at 2-8°C under sterile conditions for up to 1 month

• Extended storage after reconstitution: Store at -20°C to -70°C under sterile conditions for up to 6 months

Critical considerations:

• Use a manual defrost freezer to prevent damage from temperature fluctuations

• Avoid repeated freeze-thaw cycles which can compromise antibody activity

• Aliquot reconstituted antibody to minimize freeze-thaw cycles when possible

• Follow manufacturer's specific reconstitution instructions for optimal activity

What quality control methods can verify TL1A antibody performance over time?

Implementing routine quality control measures ensures consistent antibody performance:

• Functional validation:

  • Periodically test antibody in neutralization assays against recombinant TL1A

  • Establish ND50 values (typically 0.04-0.2 μg/mL) as performance benchmarks

  • Monitor for significant deviations which may indicate degradation

• Technical validation:

  • Run control Western blots with standard positive samples (e.g., HT-29 lysates)

  • Perform routine flow cytometry on reference cell populations

  • Compare results against historical data using standardized protocols

• Documentation approaches:

  • Maintain detailed records of storage conditions, reconstitution dates, and aliquot usage

  • Document lot-to-lot variations if using antibodies from different production batches

  • Implement a validation schedule based on frequency of use and critical application requirements

How can TL1A antibodies be used to investigate cross-talk between immune and non-immune cells?

TL1A-DR3 signaling provides an important paradigm for studying cellular cross-talk:

• Co-culture experimental design:

  • Establish endothelial-immune cell co-culture systems to model physiological interactions

  • Use antibody blocking/neutralization to dissect specific contributions of the TL1A pathway

  • Implement transwell systems to distinguish between contact-dependent and soluble mediator effects

• In situ tissue analysis approaches:

  • Employ multiplexed immunofluorescence to visualize TL1A-expressing cells in relation to DR3+ populations

  • Analyze spatial relationships between endothelial TL1A expression and immune cell infiltration

  • Correlate with markers of tissue inflammation or damage

• Functional readouts:

  • Measure immune cell activation states in the presence of TL1A-expressing non-immune cells

  • Assess reciprocal effects on endothelial activation when co-cultured with DR3-expressing lymphocytes

  • Investigate the impact of inflammatory mediators on this bidirectional communication

What methodological approaches can differentiate between membrane-bound and soluble TL1A functions?

TL1A exists in both membrane-bound and soluble forms, with potentially distinct biological activities:

• Experimental separation strategies:

  • Use recombinant soluble TL1A (encompassing Leu72-Leu251) for isolated soluble effects

  • Develop cell-based systems with membrane-anchored TL1A that cannot be cleaved

  • Compare differential signaling outcomes between these model systems

• Detection methodology:

  • Implement ELISAs to quantify soluble TL1A in biological fluids or culture supernatants

  • Use flow cytometry to measure membrane-bound TL1A on cell surfaces

  • Consider proteomics approaches to identify differential protein associations with each form

• Functional assessment:

  • Determine if receptor clustering differs between membrane and soluble ligand engagement

  • Investigate potential differences in signaling duration and intensity

  • Assess whether differential cellular responses correlate with the form of TL1A encountered